Manufacturing roundup: GenScript to boost production capacity; SK Biosciences inks MOU for its vaccine in Thailand

Gen­Script Biotech capped off an ex­pan­sion of its man­u­fac­tur­ing ca­pac­i­ty for sgR­NA and non-vi­ral DNA with a new fa­cil­i­ty in Zhen­jiang, Chi­na.

The man­u­fac­tur­er orig­i­nal­ly es­tab­lished a 21,500-square-foot plant in Nan­jing, Chi­na, which has five pro­duc­tion lines for CRISPR sgR­NA and non-vi­ral DNA pro­duc­tion. The new space in Zhen­jiang has a to­tal of 400,000 square feet for man­u­fac­tur­ing pur­pos­es and four pro­duc­tion lines.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN